Trial Profile
Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age [EXTENSION OF 700019326]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Clopidogrel (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Acronyms CLARINET-LT
- Sponsors Sanofi
- 11 Mar 2013 New trial record